Analysts expect that Dova Pharmaceuticals Inc (NASDAQ:DOVA) will post earnings of ($0.46) per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Dova Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.48) and the highest is ($0.42). The company is scheduled to report its next quarterly earnings report on Thursday, May 17th.
According to Zacks, analysts expect that Dova Pharmaceuticals will report full-year earnings of ($1.45) per share for the current financial year, with EPS estimates ranging from ($1.81) to ($0.85). For the next fiscal year, analysts forecast that the firm will report earnings of $0.47 per share, with EPS estimates ranging from ($1.65) to $3.64. Zacks’ EPS calculations are a mean average based on a survey of analysts that that provide coverage for Dova Pharmaceuticals.
Dova Pharmaceuticals (NASDAQ:DOVA) last issued its quarterly earnings data on Thursday, February 15th. The company reported ($0.36) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.36). During the same period in the prior year, the firm posted ($0.44) EPS.
A number of research firms have recently weighed in on DOVA. BidaskClub upgraded shares of Dova Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, February 16th. Evercore ISI began coverage on shares of Dova Pharmaceuticals in a research report on Friday, March 23rd. They issued a “line” rating and a $29.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and three have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $32.00.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Perceptive Advisors LLC raised its position in shares of Dova Pharmaceuticals by 3.1% in the fourth quarter. Perceptive Advisors LLC now owns 1,809,015 shares of the company’s stock valued at $52,099,000 after buying an additional 55,000 shares in the last quarter. BlackRock Inc. raised its position in shares of Dova Pharmaceuticals by 152.4% in the fourth quarter. BlackRock Inc. now owns 576,799 shares of the company’s stock valued at $16,611,000 after buying an additional 348,290 shares in the last quarter. Nexthera Capital LP raised its position in shares of Dova Pharmaceuticals by 3.4% in the fourth quarter. Nexthera Capital LP now owns 453,032 shares of the company’s stock valued at $13,047,000 after buying an additional 14,913 shares in the last quarter. Wells Fargo & Company MN raised its position in shares of Dova Pharmaceuticals by 62.1% in the third quarter. Wells Fargo & Company MN now owns 324,287 shares of the company’s stock valued at $7,874,000 after buying an additional 124,287 shares in the last quarter. Finally, Pier Capital LLC raised its position in shares of Dova Pharmaceuticals by 37.2% in the fourth quarter. Pier Capital LLC now owns 160,123 shares of the company’s stock valued at $4,612,000 after buying an additional 43,408 shares in the last quarter. Institutional investors own 26.05% of the company’s stock.
NASDAQ DOVA opened at $28.79 on Friday. Dova Pharmaceuticals has a 1-year low of $16.98 and a 1-year high of $37.00.
Dova Pharmaceuticals Company Profile
Dova Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is focused on acquiring, developing and commercializing drug candidates. The Company’s initial focus is on thrombocytopenia, a disorder characterized by a low blood platelet count. The Company is developing avatrombopag for treatment of thrombocytopenia in patients with chronic liver disease (CLD).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dova Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dova Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.